
    
      This is an open-label, non-randomized, multi-center, oral CP-690,550, multiple-dose (twice
      daily for 5 days [except Day 5 when only morning dose will be given]) study in pediatric
      subjects with JIA aged from 2 to less than 18 years. Baseline visit will occur within 1 month
      of the completion of the Screening Visit. The study will consist of three cohorts based on
      the age of the subjects, Cohort 3: 2 to less than 6 years, Cohort 2: 6 to less than 12 years
      and Cohort 1: 12 to less than 18 years. In each cohort, at least 8 pediatric subjects with
      JIA will participate in the study ensuring a total number of at least 24 pediatric evaluable
      subjects completing the PK period.
    
  